+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Diurnal Variation in Neuroendocrine Response to Stress in Rats: Plasma ACTH, β-Endorphin, β-LPH, Corticosterone, Prolactin and Pituitary Cyclic AMP Responses

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The effects of restraint stress applied at different times of the day on levels of five stress-responsive plasma hormones (ACTH, β-endorphin, β-LPH, corticosterone and prolactin) and pituitary cyclic AMP levels were assessed. Different groups of rats were subjected to 15 min of restraint stress at 2-hour intervals over a 24-hour period. Rats were sacrificed immediately upon removal from their home cage (controls) or immediately following restraint (stressed). The time of day of stress exposure markedly affected the stress responses measured. Generally, responses to stress applied at the beginning of the dark cycle (18.00) were less than those seen following stress applied at the beginning of the light cycle (06.00). Stress at 06.00 increased levels of pituitary cyclic AMP 10-fold, while stress applied at 18.00 did not significantly increase pituitary cyclic AMP levels. In stressed rats, high correlations were seen among levels of hormones derived from the common precursor, proopiomelanocortin (ACTH, β-endorphin, β-LPH) and between these hormones and levels of pituitary cyclic AMP. These findings support the hypothesis that pituitary cyclic AMP is involved in the stress-induced release or synthesis of the pituitary hormones ACTH, β-endorphin, and β-LPH.

          Related collections

          Author and article information

          S. Karger AG
          01 April 2008
          : 43
          : 3
          : 383-390
          Department of Medical Neurosciences, Walter Reed Army Institute of Research. Walter Reed Army Medical Center, Washington D.C., USA
          124553 Neuroendocrinology 1986;43:383–390
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Original Paper


          Comment on this article